Brain Tumor, Recurrent Clinical Trial
Official title:
Performance of Elucirem® (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical Trial
This trial aims to study the performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.
The trial is designed as a prospective, multi-center, randomized, controlled and parallel group comparison. This study aims to enrol 138 patients in Italy, Poland and Hungary. During the course of the trial, patient will undergo a DSC-MRI perfusion using Elucirem® or Dotarem®. A safety visit will be performed 1 day after the MRI visit. Confirmation of tumor grade diagnosis, if available, will be collected up to 30 days after visit 2. Primary end point will be assessed by independent off-site blinded readers. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
| Completed |
NCT01967810 -
ANG1005 in Patients With Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Completed |
NCT02303678 -
D2C7 for Adult Patients With Recurrent Malignant Glioma
|
Phase 1 | |
| Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
| Completed |
NCT00179907 -
A Phase I/II Study of the Photon Radiosurgery System
|
Phase 1/Phase 2 | |
| Completed |
NCT01682746 -
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
| Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
| Terminated |
NCT01966809 -
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
|
Phase 2 | |
| Completed |
NCT02458339 -
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
| Completed |
NCT00141765 -
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
|
Phase 2 | |
| Recruiting |
NCT05629702 -
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
|
Phase 2 | |
| Completed |
NCT02644460 -
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01520870 -
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
|
Phase 2 | |
| Completed |
NCT02238496 -
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
|
Phase 1 | |
| Active, not recruiting |
NCT04074785 -
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
|
Early Phase 1 |